![Zheng Bin Yao](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Zheng Bin Yao
Verkställande Direktör på
ARRIVENT BIOPHARMA, INC.
Förmögenhet: 19 M $ per 2026-05-31
Profil
Dr. Zheng Bin Yao is an Independent Director at Alumis, Inc., a Chairman & Chief Executive Officer at Arrivent BioPharma, Inc. and an Independent Non-Executive Director at VISEN Pharmaceuticals.
He is on the Board of Directors at Alumis, Inc., VISEN Pharmaceuticals, Immune-Onc Therapeutics, Inc. and NiKang Therapeutics, Inc. Dr. Yao was previously employed as a Chairman, President & Chief Executive Officer by Viela Bio, Inc., an Independent Director by NexImmune, Inc., a Senior Vice President & Head-Immuno-Oncology by MedImmune LLC, a Vice President & Head-Research by Tanox, Inc., a Head-Immuno-Oncology Franchise by AstraZeneca PLC, and a Head-Immunology & Infectious Diseases by Genentech, Inc. He received his graduate degree from Anhui Medical University and a doctorate degree from the University of Iowa.
Kända innehav i offentliga företag
| Företag | Datum | Antal aktier | Värdering | Värderingsdatum |
|---|---|---|---|---|
ARRIVENT BIOPHARMA, INC. 1,32 % | 2026-04-21 | 613 138 ( 1,32 % ) | 19 M $ | 2026-05-31 |
ALUMIS INC. 0,02 % | 2026-05-05 | 23 529 ( 0,02 % ) | 508 226 $ | 2026-05-31 |
Aktiva positioner av Zheng Bin Yao
| Företag | Position | Start |
|---|---|---|
| ALUMIS INC. | Direktör/Styrelseledamot | 2021-06-01 |
| ARRIVENT BIOPHARMA, INC. | Verkställande Direktör | 2021-06-01 |
| VISEN PHARMACEUTICALS | Direktör/Styrelseledamot | 2021-04-01 |
Immune-Onc Therapeutics, Inc.
 Immune-Onc Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company advancing novel therapies that target myeloid cells | Direktör/Styrelseledamot | 2019-04-01 |
NiKang Therapeutics, Inc.
 NiKang Therapeutics, Inc. BiotechnologyHealth Technology Develops small molecule oncology medicines to help patients | Direktör/Styrelseledamot | - |
Tidigare kända positioner av Zheng Bin Yao
| Företag | Position | Slut |
|---|---|---|
| NEXIMMUNE, INC. | Direktör/Styrelseledamot | 2024-08-27 |
| VIELA BIO, INC. | Verkställande Direktör | 2021-03-15 |
MedImmune LLC
 MedImmune LLC Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Företagsledare/Principal | 2018-02-01 |
Tanox, Inc.
 Tanox, Inc. Pharmaceuticals: MajorHealth Technology Develops antibody and pharmaceutical solutions used for the treatment of allergic diseases | Företagsledare/Principal | 2007-10-19 |
| ░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░ | - |
Zheng Bin Yaos utbildningar
Erfarenheter
Innehade positioner
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Relationer
66
Första gradens relationer
13
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
Kopplade företag
| Privata företag | 13 |
|---|---|
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Health Technology |
MedImmune LLC
MedImmune LLC Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Health Technology |
AstraZeneca PLC
 AstraZeneca PLC Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Tanox, Inc.
Tanox, Inc. Pharmaceuticals: MajorHealth Technology Develops antibody and pharmaceutical solutions used for the treatment of allergic diseases | Health Technology |
NexImmune, Inc.
 NexImmune, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biotechnology company that develops T cell immunotherapies | Health Technology |
University of Iowa
 University of Iowa Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Anhui Medical University
 Anhui Medical University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Immune-Onc Therapeutics, Inc.
Immune-Onc Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company advancing novel therapies that target myeloid cells | Health Technology |
Viela Bio, Inc.
 Viela Bio, Inc. Pharmaceuticals: MajorHealth Technology Operates as clinical-stage biotechnology company that develops treatments for inflammation and autoimmune diseases | Health Technology |
NiKang Therapeutics, Inc.
NiKang Therapeutics, Inc. BiotechnologyHealth Technology Develops small molecule oncology medicines to help patients | Health Technology |
Alumis, Inc.
 Alumis, Inc. Pharmaceuticals: MajorHealth Technology Engages in research and development of medicines for autoimmune disorders | Health Technology |
Arrivent BioPharma, Inc.
 Arrivent BioPharma, Inc. Pharmaceuticals: OtherHealth Technology Engages in development and commercialization of cancer medicines | Health Technology |
VISEN Pharmaceuticals
 VISEN Pharmaceuticals Pharmaceuticals: MajorHealth Technology Develops, manufactures and commercializes paradigm-shifting endocrine therapies | Health Technology |
